Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Living Cell Technologies Limited (LCT.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0130-0.0010 (-7.14%)
At close: 02:02PM AEST
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • W
    Welaws67
    LVCLY back from the dead. From the latest PR:

    "The one year follow up of the 18 patients in the Phase IIb study of NTCELL® for Parkinson’s disease shows a statistically significant improvement change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery..The Data Safety Monitoring Board has advised that there are no safety issues arising from the data."
  • E
    Eli B
    The Alzheimer's Association estimates that, "caring for individuals with Alzheimer's will cost American society $20 trillion."

    Jim Cramer says a drug that could treat the disease "would be the biggest drug ever."

    The Wall Street Journal says the "financial benefits would be massive."

    One small biotech holds the key to a revolution in treating this dreaded disease.
  • E
    Eli B
    As decision day nears, one analyst suggests investors buckle their seat belts in anticipation of big moves in Biogen stock, as well as gyrations in the shares of other companies that have Alzheimer’s treatments or may be takeover targets for Biogen, such as Esai, the company’s partner on aducanumab.
  • b
    bocamp1
    Congrats to SOC...........
  • r
    rc471980
    1 APR 2022 8:46 AM AEDTShare
    NTCELL to be produced in Australia under UTS research agreement
    Living Cell Technologies (ASX:LCT) says it has advanced plans for a third clinical trial of NTCELL in Parkinson’s disease.

    The company said this follows the signing of a research agreement with the University of Technology Sydney (UTS) and the Australian Foundation for Diabetes Research (AFDR).

    The agreement will allow university facilities to be used to optimise the production of NTCELL in Australia for the first time, prior to the third clinical trial.

    Once approved by import authorities, porcine brain tissue (choroid plexus) will be shipped to Sydney from research partner NZeno’s pig facility in New Zealand.

    Living Cell Technologies said once the Australian production of NTCELL has been optimised at UTS, the tissue will be sent to a Good Manufacturing Practice facility, where it will be manufactured under conditions suitable for it to be used clinically.

    Approval for the use of the encapsulated pig tissue will need to be obtained from a Human Research Ethics Advisory Committee and the TGA.

    The NTCELL clinical trial for people with early to mid-stage Parkinson’s disease is likely to be the first xenotransplantation trial carried out in Australia after earlier trials in New Zealand.

    LCT executive chairman Professor Bernie Tuch said, “This is another key step as we advance this potentially groundbreaking research in Australia, following in the footsteps of New Zealand researchers.

    “Optimising the production of encapsulation pig choroid plexus in Australia is a necessary measure before it is manufactured under GMP conditions for the clinical trial.

    “We look forward to getting this work underway as soon as possible, given the pressing need for new treatments for Parkinson’s disease and its impact on the community.”

    The company said the first trial participants are expected to receive treatment in 2024.
  • D
    David
    mentioned in scientific American December issue? time will.tell
  • E
    Eli B
  • B
    Billl
    Pig hearts could soon be tested in humans after scientists pass important milestone

    Pig hearts could soon be tested in humans after scientists passed an important milestone when transplanting the organs into primates.

    In 2000, the International Society for Heart and Lung Transplantation (ISHLT)suggested that human trials would be considered once 60 per cent of primates could live for three months, with at least some indication that longer survival was possible.

    Previous studies have only achieved up to 57 days survival, so the new research is the first to meet the criteria set out by the ISHLT, and represents a major step in the clinical use of pig hearts in humans.

    Now surgeons in Germany, using hearts from pigs that had been genetically modified to remove threatening viruses...
    Latest news, business, sport, comment, lifestyle and culture from the Daily Telegraph and Sunday Telegraph newspapers and video from Telegraph TV.
    Latest news, business, sport, comment, lifestyle and culture from the Daily Telegraph and Sunday Telegraph newspapers and video from Telegraph TV.
    www.telegraph.co.uk
  • A
    Anonymous
    It should go higher every month thru 2017
  • B
    Billl
    well well well...maybe this is the breakout??!
  • B
    Billl
    $1.00 on news....?
  • P
    Philip E
    Do we expect a big up day based on the news?
  • B
    Billl
    morning....do I see some action?
  • P
    Philip E
    Does anyone know how long it takes to recover from putting NT Cells into the brain?
  • B
    Billl
    Hmmmm what's up??
  • B
    Billl
    HEY..Hey.. Close over a Buck on First trade day if April....?? $1.50 on First trade day in July 17??!
  • B
    Billl
    NTCELL Clinical Study results to be announced on Friday 10 November

    Results of NTCELL® Clinical Study in Parkinson’s 

    Results released to ASX on Friday 10 November

    Company to host conference call on Friday 10 November at 2:00pm AEST / 4:00pm NZT

    LCT has announced a trading halt ahead of the announcement of the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on Friday 10 November. 

    Investor call

    LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on the day of the announcement.

    Date: Friday 10 November 2017
    Time: NZT 4:00pm, AEST 2:00pm 

    Conference ID: 3389168

    Toll-free dial-in numbers for participants:
    Australia - 1800 123 296
    New Zealand - 0800 452 782
    Canada - 1855 5616 766
    China - 4001 203 085
    Hong - Kong 800 908 865
    India - 1800 3010 6141
    Japan - 0120 985 190
    Singapore - 800 616 2288
    United Kingdom - 0808 234 0757
    United States - 1855 293 1544
    or
    toll +61 2 8038 5221
  • F
    Flatch
    Up 23% today and not a wit of information. This stock is a lock box on what's going on. Whatever, it's gotta be good.
  • m
    m1properties
    Head fake
  • B
    Billl
    Hearing rumors trials results will be reported in November and time to put on happy face... hmmmm hope so. been a long ride..... bet on the Pigs !!!
Advertisement
Advertisement